Catalyst Wire Dossier Catalyst Wire Dossier

Certolizumab pegol (lyophilized formulation)

certolizumab pegol · UCB Pharma
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Certolizumab pegol (lyophilized formulation), covering 2013-03-08 to 2013-03-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis [Phase 3]

See pricing